Rentschler Biopharma logo from PR.jpg
Rentschler Biopharma adds highly experienced executive to team and provides update on progress at Rentschler ATMP
June 13, 2022 10:00 ET | Rentschler Biopharma SE
Company hires Kassim Kolia, as Vice President, Business Development to grow cell and gene therapy businessStevenage ATMP site projected to be client ready for process development in late 2022 ...
Almac Pharma Services Expands Its Unique Ultra-Low Temperature Solutions for Advanced Therapy Medicinal Products
March 14, 2022 12:31 ET | Almac Group
CRAIGAVON, Northern Ireland, March 14, 2022 (GLOBE NEWSWIRE) -- Almac Pharma Services, a member of the Almac Group providing innovative pharmaceutical development, manufacture and commercial...
GMILogo_Vertical-Gradient.png
Phosphonates Market worth $1.5 Billion by 2027, Says Global Market Insights Inc.
March 09, 2022 04:30 ET | Global Market Insights Inc.
Selbyville, Delaware, March 09, 2022 (GLOBE NEWSWIRE) -- Global phosphonates market value is anticipated to cross USD 1.5 billion by 2027, according to a new research report by Global Market...
Bone Therapeutics provides fourth quarter 2021 business update and 2022 outlook
January 19, 2022 01:00 ET | Bone Therapeutics SA
REGULATED INFORMATION Recruitment for ALLOB tibial facture Phase IIb study ongoing and on schedule to release topline data in Q1 2023, despite COVID slowdown New scientific advisory...
Bone Therapeutics fait le point sur ses activités au quatrième trimestre 2021 et sur ses perspectives de développement en 2022
January 19, 2022 01:00 ET | Bone Therapeutics SA
INFORMATION RÉGLEMENTÉE Poursuite active du recrutement pour l’essai de Phase IIb évaluant ALLOB dans les fractures du tibia. Présentation des données principales au premier trimestre 2023,...
Bone Therapeutics signe un partenariat de recherche avec Implant Therapeutics pour garantir son accès à des Cellules Souches Pluripotentes induites (CSPi)
September 28, 2021 01:00 ET | Bone Therapeutics SA
INFORMATION REGLEMENTEE Bone Therapeutics bénéficiera de l’expertise d’Implant Therapeutics et pourra accéder à des lignées cellulaires Souches Pluripotentes induites (SPi), incluant des...
Bone Therapeutics signs research partnership with Implant Therapeutics to access induced Pluripotent Stem Cells (iPSC)
September 28, 2021 01:00 ET | Bone Therapeutics SA
REGULATED INFORMATION Bone Therapeutics will gain access to iPS cell lines, including hypoimmunogenic cell lines, differentiation protocols and expertise iPSC technology allows for the...
Immunicum erhåller Advanced Therapy Medicinal Product-klassificering från EMA för vaccinkandidaten mot canceråterfall, DCP-001
June 28, 2021 02:00 ET | Immunicum AB
Pressmeddelande 28 Juni 2021 Immunicum erhåller Advanced Therapy Medicinal Product-klassificering från EMA för vaccinkandidaten mot canceråterfall, DCP-001 Immunicum AB tillkännagav idag att...
Immunicum Receives Advanced Therapy Medicinal Product Classification from the EMA for Cancer Relapse Vaccine Candidate DCP-001
June 28, 2021 02:00 ET | Immunicum AB
Press Release 28 June 2021 Immunicum Receives Advanced Therapy Medicinal Product Classification from the EMA for Cancer Relapse Vaccine Candidate DCP-001 Immunicum AB (publ) today announced that...
Bone Therapeutics annonce les résultats de son Assemble Générale Annuelle
June 10, 2021 01:00 ET | Bone Therapeutics SA
Approbation de l’ensemble des résolutions par les actionnaires Gosselies, Belgique, le 10 juin 2021, 7h00 CEST – BONE THERAPEUTICS (Euronext Bruxelles et Paris : BOTHE), société de...